Benjamin F. Edwards & Company Inc. increased its position in UnitedHealth Group Incorporated (NYSE:UNH) by 19.1% during the first quarter, according to its most recent filing with the SEC. The institutional investor owned 1,642 shares of the healthcare conglomerate’s stock after buying an additional 263 shares during the period. Benjamin F. Edwards & Company Inc.’s holdings in UnitedHealth Group were worth $269,000 at the end of the most recent quarter.

Several other large investors also recently made changes to their positions in UNH. Jackson Grant Investment Advisers Inc. boosted its stake in shares of UnitedHealth Group by 0.4% in the fourth quarter. Jackson Grant Investment Advisers Inc. now owns 1,093 shares of the healthcare conglomerate’s stock worth $175,000 after buying an additional 4 shares in the last quarter. Adirondack Trust Co. boosted its stake in shares of UnitedHealth Group by 0.5% in the first quarter. Adirondack Trust Co. now owns 990 shares of the healthcare conglomerate’s stock worth $162,000 after buying an additional 5 shares in the last quarter. Paradigm Financial Advisors LLC boosted its stake in shares of UnitedHealth Group by 0.4% in the first quarter. Paradigm Financial Advisors LLC now owns 2,761 shares of the healthcare conglomerate’s stock worth $452,000 after buying an additional 11 shares in the last quarter. Harwood Advisory Group LLC boosted its stake in shares of UnitedHealth Group by 0.8% in the first quarter. Harwood Advisory Group LLC now owns 1,885 shares of the healthcare conglomerate’s stock worth $309,000 after buying an additional 15 shares in the last quarter. Finally, Trust Co boosted its stake in shares of UnitedHealth Group by 0.4% in the fourth quarter. Trust Co now owns 5,056 shares of the healthcare conglomerate’s stock worth $809,000 after buying an additional 20 shares in the last quarter. Institutional investors own 86.26% of the company’s stock.

UnitedHealth Group Incorporated (NYSE:UNH) traded up 0.06% during mid-day trading on Friday, hitting $194.88. The stock had a trading volume of 2,791,318 shares. The stock has a market capitalization of $191.96 billion, a P/E ratio of 23.41 and a beta of 0.64. UnitedHealth Group Incorporated has a 52 week low of $132.39 and a 52 week high of $196.04. The company’s 50 day moving average is $186.80 and its 200-day moving average is $173.05.

UnitedHealth Group (NYSE:UNH) last posted its earnings results on Tuesday, July 18th. The healthcare conglomerate reported $2.46 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $2.38 by $0.08. UnitedHealth Group had a return on equity of 21.52% and a net margin of 4.32%. The business had revenue of $50.05 billion during the quarter, compared to analysts’ expectations of $49.97 billion. During the same period in the previous year, the business earned $1.96 earnings per share. The firm’s revenue was up 7.7% on a year-over-year basis. On average, analysts expect that UnitedHealth Group Incorporated will post $9.87 EPS for the current fiscal year.

WARNING: This report was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this report on another domain, it was stolen and reposted in violation of US & international trademark and copyright law. The original version of this report can be accessed at https://www.thecerbatgem.com/2017/08/04/benjamin-f-edwards-company-inc-acquires-263-shares-of-unitedhealth-group-incorporated-nyseunh-updated-updated-updated.html.

A number of brokerages have recently issued reports on UNH. UBS AG reiterated a “buy” rating and set a $194.00 price objective (up previously from $193.00) on shares of UnitedHealth Group in a research note on Saturday, April 22nd. Cantor Fitzgerald reiterated an “overweight” rating and set a $205.00 price objective (up previously from $200.00) on shares of UnitedHealth Group in a research note on Saturday, April 22nd. Sanford C. Bernstein reiterated an “outperform” rating and set a $190.00 price objective on shares of UnitedHealth Group in a research note on Monday, July 10th. Credit Suisse Group restated an “outperform” rating and issued a $200.00 price target (up previously from $195.00) on shares of UnitedHealth Group in a research note on Thursday, July 13th. Finally, Citigroup Inc. increased their price target on UnitedHealth Group from $195.00 to $213.00 and gave the company a “buy” rating in a research note on Wednesday, July 19th. One equities research analyst has rated the stock with a hold rating and twenty-four have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $200.24.

In other news, Director Gail R. Wilensky sold 5,540 shares of the company’s stock in a transaction dated Friday, June 2nd. The stock was sold at an average price of $178.74, for a total value of $990,219.60. Following the completion of the transaction, the director now directly owns 60,516 shares in the company, valued at approximately $10,816,629.84. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director William C. Ballard, Jr. sold 5,000 shares of the company’s stock in a transaction dated Wednesday, June 7th. The stock was sold at an average price of $182.64, for a total value of $913,200.00. Following the completion of the transaction, the director now owns 75,735 shares of the company’s stock, valued at $13,832,240.40. The disclosure for this sale can be found here. 0.89% of the stock is currently owned by corporate insiders.

About UnitedHealth Group

UnitedHealth Group Incorporated is a health and well-being company. The Company operates through four segments: UnitedHealthcare, OptumHealth, OptumInsight and OptumRx. It conducts its operations through two business platforms: health benefits operating under UnitedHealthcare and health services operating under Optum.

Institutional Ownership by Quarter for UnitedHealth Group (NYSE:UNH)

Receive News & Stock Ratings for UnitedHealth Group Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UnitedHealth Group Incorporated and related stocks with our FREE daily email newsletter.